Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115348 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Kexin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Pharmacy, Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, S…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Receptors, CXCR4, Liver Cirrhosis, Phosphate-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: West China Hospital of Medicine, Fundamental Research Funds for the Central Universities, Ministerul Educaţiei Naţionale.
Abstract (Originalsprache)
Liver fibrosis is a progressive pathological disorder characterized by excessive extracellular matrix (ECM) deposition, resulting in hepatic architectural distortion and functional impairment. Despite its clinical importance, effective therapeutic options remain limited. This study evaluated the antifibrotic potential of senkyunolide I (SI), a bioactive phthalide compound derived from Ligusticum chuanxiong Hort., in both in vivo and in vitro models. In a CCl4-induced mouse model of liver fibrosis, SI treatment significantly attenuated fibrosis progression, as indicated by a reduced liver index, decreased serum ALT and AST levels, diminished histopathological damage, suppressed collagen deposition, and ameliorated hepatocyte ultrastructural injury. Additionally, SI inhibited hepatic inflammation by modulating the CXCR4/NLRP3/GSDMD pathway. In vitro experiments demonstrated that SI effectively mitigated LPS + nigericin (Nig)-induced pyroptosis in AML-12 cells and reduced collagen deposition in primary hepatic stellate cells (HSCs) exposed to conditioned medium from injured hepatocytes. Mechanistic studies revealed that SI directly binds to CXCR4, suppressing its expression and subsequently inactivating the NLRP3/GSDMD signalling cascade. These findings suggest that SI exerts its antifibrotic effects via CXCR4 pathway inhibition, positioning it as a promising therapeutic candidate for liver fibrosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- West China School of Pharmacy, Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
- Laboratory of Quality and Innovation Research of Chinese Materia Medica, Sichuan Academy of Chinese Medicine, Chengdu, Sichuan, China.
- West China School of Pharmacy, Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: dujunr…
- Laboratory Medicine Center, Sichuan Provincial Women's and Children's Hospital, Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, Sichuan, China. Electronic address: Longfangyi1206@163.com.
Förderung
- West China Hospital of Medicine
- Fundamental Research Funds for the Central Universities
- Ministerul Educaţiei Naţionale
- Higher Education Discipline Innovation Project
Zitieren
APA
Wang, K., Yang, Y., Yue, B., Li, M., Chen, C., Du, J., & Long, F. (2025). Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115348
Vancouver
Wang K, Yang Y, Yue B, Li M, Chen C, Du J, et al. Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115348
BibTeX
@article{Wang2025,
author = {Wang, Kexin and Yang, Yuxin and Yue, Bingjie and Li, Mengyang and Chen, Chu and Du, Junrong and Long, Fangyi},
title = {Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115348}
}
EUVIMED